6/29/23, 1:37 AM PAUSE-SCD Pathway Feedback Search Clinical Topics Home Studies PAUSE SCD PAUSE SCD DiseaseDilated cardiomyopathy DiseaseHypertrophic cardiomyopathy DiseaseVentricula Trial question Is first-line catheter ablation therapy superior to conventional medical therapy in patients with cardiomyopathy of varied etiologies? Study design Multi-center Open label RCT Population Characteristics of study participants 19.0% female N = 121 81.0% male 121 patients (23 female, 98 male) Inclusion criteria: patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation Key exclusion criteria: acute STEMI within 60 days; revascularization within 45 days; reversible causes of VT or cardiomyopathy; LVEF < 15%; HF; life expectancy < 1 year Interventions N=60 ablation therapy (early ablation therapy plus ICD implantation) N=61 conventional therapy (medical therapy plus ICD implantation) Primary outcome https://web.pathway.md/studies/rectLsXUcySv8vvSz 1/2 6/29/23, 1:37 AM PAUSE-SCD Pathway Composite outcome of ventricular tachycardia recurrence, cardiovascular hospitalization or death 65.5 % 65.5 49.1 % 49.3 32.8 % Significant decrease 16.4 % NNT = 6 0.0 % Ablation therapy Conventional therapy Significant decrease in composite outcome of VT recurrence, cardiovascular hospitalization or death (49.3% vs. 65.5%; HR 0.58, 95% CI 0.35 to 0.96) Secondary outcomes Significant decrease in VT recurrence (31.7% vs. 50.8%; HR 0.51, 95% CI 0.29 to 0.9) No significant difference in cardiovascular hospitalization (28.3% vs. 32.8%; HR 0.82, 95% CI 0.43 to 1.56) No significant difference in death from any cause (8.3% vs. 6.6%; HR 1.4, 95% CI 0.38 to 5.22) Safety outcomes Significant difference in ablation-related complications (8.3% vs. 0%). Conclusion In patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation, ablation therapy was superior to conventional therapy with respect to the composite outcome of VT recurrence, cardiovascular hospitalization or death. Reference Roderick Tung, Yumei Xue, Minglong Chen et al. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent with Defibrillator Implantation: The PAUSE- SCD Randomized Trial. Circulation. 2022 Jun 21;145(25):1839-1849. Open reference URL https://web.pathway.md/studies/rectLsXUcySv8vvSz 2/2